Upcoming Milestones

4/12: Sickle Cell Disease — Draft Evidence Report Learn more

ICER will release our Draft Evidence Report on exagamglogene autotemcel (“exa-cel”, Vertex Pharmaceuticals and CRISPR Therapeutics) and lovotibeglogene autotemcel (“lovo-cel”, bluebird bio) for the treatment of sickle cell disease.

The Draft Report will be open to public comment until May 9th.

4/13: NASH Revised Evidence Report Learn more

After about one month of receiving public comments, ICER will publish a revised Evidence Report assessing the comparative clinical effectiveness and value of resmetirom (Madrigal Pharmaceuticals, Inc.) and obeticholic acid (Ocaliva®, Intercept Pharmaceuticals, Inc.) for non-alcoholic steatohepatitis (NASH).

4/17: Alzheimer’s Disease — Final Evidence Report Learn more

At ICER’s 3/17 public meeting on Leqembi for Alzheimer’s disease, ICER’s independent appraisal committee reviewed the evidence, heard further testimony from stakeholders, and deliberated over the treatment’s comparative clinical effectiveness, other potential benefits, and long-term value for money.

Please find the public meeting recordings below:

ICER’s Final Report and Meeting Summary will be available on 4/17.

Our Origin Story.

ICER President Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.

The ICER Impact.

New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million

Read More

Engaged with over 300 patient groups and patient reps

In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model

Read More



In 2021, we celebrated our 15th anniversary! Learn more.

cheerful creative patients sitting in a circle laughing

We recently published a commentary in Health Affairs about one-time treatments like Zynteglo and Hemgenix. In both of these ICER reports, we analyzed a “shared savings” scenario, which suggests how manufacturers of these one-time therapies, instead of capturing all the avoided downstream medical costs in one giant price tag, could set a lower price and therefore share the innovation windfall with society. Read the full article here.

ICER podcast logo

Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.


Policy Papers.

Easy access to our latest policy papers

Barriers to Fair Access

Second annual scorecard of barriers to fair access criteria; during ICER’s assessment, five payers revised policies for 11 drugs in ways that bring coverage into concordance with fair access criteria, demonstrating that assessment and greater transparency may lead to positive change

Read More

Unsupported Price Increases

Seven out of 10 high-expenditure drugs had substantial 2021 net price increases that were not supported by new clinical evidence; these increases accounted for $805 million in additional costs over one year.

Additionally, three Medicare Part B drugs with high list price increases in 2020 lacked adequate supporting new evidence, directly raising annual out-of-pocket expenses for Medicare patients by up to $3,200 per year.

Read More

Evaluating and Advancing Health Technology Assessment Methods that Support Health Equity

ICER received a new grant from The Commonwealth Fund to evaluate procedural and methodological changes that could further support health equity goals in health technology assessment (HTA). The findings from this effort will guide ICER’s update to its value assessment framework and inform the work of other HTA groups worldwide.

Read More

Cost-Effectiveness, the evLYG,

the QALY, and Fair Drug Pricing.

Learn More.